PubMed HealthSearch

PubMed · 7993992

Contrast nephrotoxicity.

Abstract

Iodinated contrast media have some nephrotoxic potential but rarely cause significant renal failure in patients with normally functioning kidneys. Patients with existing renal impairment, with or without diabetes, those with current congestive heart failure of Class III or IV, those with reduced effective arterial volume (e.g., nephrotic, cirrhotic), or those receiving drugs that may impair renal function or increase contrast nephrotoxicity are at higher risk. Contrast nephrotoxicity may be clinically important in patients with other factors simultaneously affecting the renal response to contrast or in whom acute renal failure would seriously affect prognosis. The pathogenesis of contrast nephrotoxicity probably involves a combination of direct tubular toxicity and renal ischemic injury. Knowledge of the pathogenetic pathways is accumulating and is leading to the discovery of rational specific prophylactic measures to reduce the burden of nephrotoxicity. After the efficacy of these measures has been established, they should be considered for use in patients at high risk. Existing data indicate a limited role for the newer low-osmolality media for the prevention of nephrotoxicity.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B J Barrett. 1994. Contrast nephrotoxicity.. https://doi.org/10.1681/asn.v52125

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics.

Early transplant dysfunction and failure because of immunological and nonimmunological factors still presents a significant clinical problem for transplant recipients. A critical unmet need is the noninvasive detection and prediction of immune injury such that acute injury can be reversed by proactive immunosuppression titration. In this study, we used iTRAQ -based proteomic discovery and targeted ELISA validation to discover and validate candidate urine protein biomarkers from 262 renal allograft recipients with biopsy-confirmed allograft injury. Urine samples were randomly split into a training set of 108 patients and an independent validation set of 154 patients, which comprised the clinical biopsy-confirmed phenotypes of acute rejection (AR) (n = 74), stable graft (STA) (n = 74), chronic allograft injury (CAI) (n = 58), BK virus nephritis (BKVN) (n = 38), nephrotic syndrome (NS) (n = 8), and healthy, normal control (HC) (n = 10). A total of 389 proteins were measured that displayed differential abundances across urine specimens of the injury types (p < 0.05) with a significant finding that SUMO2 (small ubiquitin-related modifier 2) was identified as a "hub" protein for graft injury irrespective of causation. Sixty-nine urine proteins had differences in abundance (p < 0.01) in AR compared with stable graft, of which 12 proteins were up-regulated in AR with a mean fold increase of 2.8. Nine urine proteins were highly specific for AR because of their significant differences (p < 0.01; fold increase >1.5) from all other transplant categories (HLA class II protein HLA-DRB1, KRT14, HIST1H4B, FGG, ACTB, FGB, FGA, KRT7, DPP4). Increased levels of three of these proteins, fibrinogen beta (FGB; p = 0.04), fibrinogen gamma (FGG; p = 0.03), and HLA DRB1 (p = 0.003) were validated by ELISA in AR using an independent sample set. The fibrinogen proteins further segregated AR from BK virus nephritis (FGB p = 0.03, FGG p = 0.02), a finding that supports the utility of monitoring these urinary proteins for the specific and sensitive noninvasive diagnosis of acute renal allograft rejection.

Acute Kidney Injury